search
Back to results

CrYobiopsy With Radial UltraSound Guidance (CYRUS)

Primary Purpose

Pulmonary Disease

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Radial Endobronchial Ultrasound Probe
Flouroscopy
Sponsored by
Vanderbilt University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Pulmonary Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Referral to interventional pulmonary services for diagnostic transbronchial cryobiopsy for diffuse parenchymal lung disease.
  2. Transbronchial cryobiopsy is determined to be appropriately indicated as determined by consulting interventional pulmonologist.
  3. Age > 18 years

Exclusion Criteria:

  1. Inability to provide informed consent
  2. Study subject has any condition that interferes with safe completion of the study including:

    1. Coagulopathy, with criteria left at the discretion of the operator
    2. Respiratory insufficiency with DLCO < 30% or baseline requirements of oxygen >2 liters
    3. Hemodynamic instability with systolic blood pressure <90 mmHg or heart rate > 120 beats/min, unless deemed to be stable with these values by the attending physicians
  3. Patients representing vulnerable populations (prisoners, pregnant women, etc.)

Sites / Locations

  • Vanderbilt University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Experimental

Arm Label

Control

Intervention

Arm Description

Standard of Care - Transbronchial cryobiopsies are obtained as a standard of care under fluoroscopy guidance

In the intervention arm , radial ultrasound probe will be used in addition to standard of care described above to confirm adequate position of the cryoprobe before transbronchial cryobiopsy is obtained.

Outcomes

Primary Outcome Measures

Time to Achieve Hemostasis After Obtaining Cryobiopsy
This is defined as time from when the bronchoscope and cryoprobe are removed en bloc after obtaining the cryobiopsy to the time when it is determined to be safe to proceed to next cryobiopsy("Ready for next biopsy").

Secondary Outcome Measures

Grade of Bleeding
0)No or only scant bleeding, stops spontaneously Mild, stops with suction or iced saline or scope tamponade Modest, stops with balloon blockade < 3 min Moderate,requires bleeding side down in addition to balloon Severe, requires prolonged blockade (> 3 min) Very severe,soils opposite lung, hypoxemia, increase level of care, additional procedures All participants received both interventions during the same procedure.
Number of Biopsies That Required Additional Interventions to Manage Bleeding
Cold saline, patient positioning, rigid bronchoscopy, embolization, ICU admission etc. are techniques to control bleeding after cryobiopsy. Use of these techniques will be recorded.
Biopsy Specimen Quality
Each biopsy obtained will be assessed by pathologist for quality of sample obtained and injury patterns identified
Biopsy Size
Each biopsy obtained will be assessed by pathologist for size of sample obtained.

Full Information

First Posted
March 7, 2018
Last Updated
October 23, 2019
Sponsor
Vanderbilt University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03506295
Brief Title
CrYobiopsy With Radial UltraSound Guidance
Acronym
CYRUS
Official Title
CrYobiopsy With Radial UltraSound Guidance (CYRUS)...
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
April 6, 2018 (Actual)
Primary Completion Date
October 3, 2018 (Actual)
Study Completion Date
October 3, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes

5. Study Description

Brief Summary
Transbronchial cryobiopsy carries a higher chance of establishing pathological diagnosis in diffuse parenchymal lung disease (DPLD) than traditional transbronchial forceps guided biopsy. It is a novel technique capable of obtaining large, high-quality samples of lung tissue in a minimally invasive manner. This procedure may decrease the need for surgical lung biopsy in 75% of cases. However, there is an increased risk of pneumothorax and airway bleeding compared to traditional transbronchial forceps guided biopsy. Several strategies are used by practitioners of this technique to mitigate the risks of significant bleeding and pneumothorax. These include prophylactic placement of an endobronchial blocker, the use of fluoroscopy guidance, instillation of cold saline to promote vasoconstriction, and establishment of a secure airway with endotracheal tube placement or rigid bronchoscopy . Vanderbilt University Medical Center is one of the most active centers in terms of cryobiopsies performed as part of the diagnostic workup of DPLD. Currently all transbronchial cryobiopsies here are performed under fluoroscopic guidance, with endotracheal tube intubation and endobronchial blocker placement. Despite these precautions, post biopsy bleeding complications occur and can substantially lengthen the duration of the procedure and occasionally expose patients to procedural complications. Radial ultrasound has been well utilized to define anatomy of peripheral lung and localization of peripheral pulmonary nodules. We postulate that using radial ultrasound to identify peribronchial lung parenchyma with low vascularity will mitigate the risk of hemorrhage during peripheral lung cryobiopsy in patients with DPLD and hence improve patient safety.
Detailed Description
Diffuse parenchymal lung diseases comprise a group of noninfectious, non-neoplastic lung diseases, each characterized by varying degrees of inflammation or fibrosis of the parenchyma of both lungs. The differentiation of these disorders may require biopsy material, particularly in patients with atypical clinical or radiological presentations. Cryobiopsies offer specialists the advantage of being able to collect much larger specimens than can be collected with forceps biopsy, while preserving the underlying lung architecture (no crush artifact). The biggest disadvantage of cryobiopsy is a higher risk of procedural bleeding and, to a lesser extent, pneumothorax than conventional transbronchial lung biopsies. Existing cryobiopsy literature is significantly limited by lack of procedure standardization, variable diagnostic endpoints and non-uniform grading of complications. Surgical lung biopsy, currently the gold standard for histological diagnosis of DPLD, is associated with significant morbidity and mortality. The rate of in-hospital mortality following SLB for DPLD was recently found to be 1.7% in a large dataset, with a complication rate of 30% (including post-operative pneumothorax, pneumonia, respiratory failure). Mortality was slightly lower at 1.5% for elective operations but markedly higher at 16% for operations labeled "non-elective," presumably performed in the setting of acute disease exacerbations. Clearly, less invasive strategies, such as cryobiopsy, are urgently needed. Recent studies demonstrate that there might be a trend toward more bleeding complications with transbronchial cryobiopsies. The increased risk of bleeding is due to the larger biopsies thus obtained, and the necessity to retrieve bronchoscope and cryoprobe en-bloc as biopsies are too large to be pulled through he working channel of the bronchoscope, preventing the proceduralist from keeping he bronchoscope wedged in the biopsied segment allowing bleeding tamponade. Accordingly, most proceduralists perform cryobiopsy with prophylactic placement of bronchial blocker positioned proximal to the selected lobe to occlude the segmental airway after biopsy. While this technique has essentially eliminated the risk of life-threatening bleeding after cryobiopsies, significant bleeding complications persist and can occasionally substantially lengthen the duration of the procedure, leading to premature termination and potentially quantitatively inadequate biopsy acquisition. Conceptually it seems that the ability to select a less vascular area for a somewhat larger cryobiopsy may result in decreased risk of hemorrhage and/or reduction in bleeding severity. Average peripheral cryobiopsy size varies significantly and may be dependent on freezing time and cryoprobe size. Increase in resource utilization due to the use of radial ultrasound could be offset by a decrease in complication rate, decreased procedural time and potentially decreased endobronchial blocker need. This use of radial probe ultrasound use has not been widely reported in literature except for a recent single center retrospective review of 10 patients undergoing transbronchial cryobiopsies for ILD(Berim, 2017). Six of these patients underwent vascular localization with radial probe endobronchial localization with trends towards less bleeding. The purported benefit of radial ultrasound-guided transbronchial cryobiopsy is the avoidance of excessive bleeding, which has been associated with this procedure. With the systematic use of a prophylactic bronchial blocker, an ideal endpoint for this pilot study would be the time spent obtaining each biopsy. We propose to study in a prospective, double-blind, randomized controlled fashion, the efficacy of radial endobronchial ultrasound (in combination with fluoroscopy) guided transbronchial cryobiopsy as compared to conventional fluoroscopy guided cryobiopsy in reducing time needed to achieve hemostasis (primary endpoint) and need for additional modalities to control bleeding and size of biopsies obtained (secondary endpoints).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Disease

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Masking Description
Primary bronchoscopist will perform localization of biopsy spot, after biopsy is determined to be in the control or intervention group. He/she will then perform the cryobiopsy per protocol. A bedside assistant will assist in managing the endobronchial blocker at all times. Secondary bronchoscopist will be stationed outside the operating room during initial part of the procedure. He will be prompted to enter the room by research coordinator to take control of the bronchoscope and assess post cryobiopsy bleeding. He will hence be blinded to the use or non-use of radial probe ultrasound. Research coordinator will be present at all times and will coordinate the switching process between proceduralists. Reference image of the radial USG determining the biopsy location on fluoroscopy monitor will be erased before secondary bronchoscopist enters the room. Patient will be blinded as he/she will be sedated. Four biopsies will be planned per procedure, two each from control & intervention arm.
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
Other
Arm Description
Standard of Care - Transbronchial cryobiopsies are obtained as a standard of care under fluoroscopy guidance
Arm Title
Intervention
Arm Type
Experimental
Arm Description
In the intervention arm , radial ultrasound probe will be used in addition to standard of care described above to confirm adequate position of the cryoprobe before transbronchial cryobiopsy is obtained.
Intervention Type
Device
Intervention Name(s)
Radial Endobronchial Ultrasound Probe
Intervention Description
The radial EBUS procedure is performed by inserting a miniature ultrasound probe (radial EBUS probe) through the working channel of a flexible bronchoscope or catheter (guide sheath). Real-time imaging of the surrounding tissue enables the clinician to determine the lesion's exact location and size.
Intervention Type
Device
Intervention Name(s)
Flouroscopy
Intervention Description
Real-time fluoroscopy will be used in all cases to guide the radial probe ultrasound and/or cryobiopsy probe placement.
Primary Outcome Measure Information:
Title
Time to Achieve Hemostasis After Obtaining Cryobiopsy
Description
This is defined as time from when the bronchoscope and cryoprobe are removed en bloc after obtaining the cryobiopsy to the time when it is determined to be safe to proceed to next cryobiopsy("Ready for next biopsy").
Time Frame
From time of randomization up to 120 minutes.
Secondary Outcome Measure Information:
Title
Grade of Bleeding
Description
0)No or only scant bleeding, stops spontaneously Mild, stops with suction or iced saline or scope tamponade Modest, stops with balloon blockade < 3 min Moderate,requires bleeding side down in addition to balloon Severe, requires prolonged blockade (> 3 min) Very severe,soils opposite lung, hypoxemia, increase level of care, additional procedures All participants received both interventions during the same procedure.
Time Frame
From time of randomization up to 120 minutes.
Title
Number of Biopsies That Required Additional Interventions to Manage Bleeding
Description
Cold saline, patient positioning, rigid bronchoscopy, embolization, ICU admission etc. are techniques to control bleeding after cryobiopsy. Use of these techniques will be recorded.
Time Frame
From time of randomization up to 120 minutes.
Title
Biopsy Specimen Quality
Description
Each biopsy obtained will be assessed by pathologist for quality of sample obtained and injury patterns identified
Time Frame
From time of randomization until acquisition of results from pathology, assessed up to 12 months.
Title
Biopsy Size
Description
Each biopsy obtained will be assessed by pathologist for size of sample obtained.
Time Frame
From time of randomization until acquisition of results from pathology, assessed up to 12 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Referral to interventional pulmonary services for diagnostic transbronchial cryobiopsy for diffuse parenchymal lung disease. Transbronchial cryobiopsy is determined to be appropriately indicated as determined by consulting interventional pulmonologist. Age > 18 years Exclusion Criteria: Inability to provide informed consent Study subject has any condition that interferes with safe completion of the study including: Coagulopathy, with criteria left at the discretion of the operator Respiratory insufficiency with DLCO < 30% or baseline requirements of oxygen >2 liters Hemodynamic instability with systolic blood pressure <90 mmHg or heart rate > 120 beats/min, unless deemed to be stable with these values by the attending physicians Patients representing vulnerable populations (prisoners, pregnant women, etc.)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fabien Maldonado, MD
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States

12. IPD Sharing Statement

Learn more about this trial

CrYobiopsy With Radial UltraSound Guidance

We'll reach out to this number within 24 hrs